Floatz logo

Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells

Hodgkin Disease

Medical College of WisconsinCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

149 Active assets in the Hodgkin Disease cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
anaplastic large cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
primary cutaneous anaplastic large cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →